Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease
Nobuharu Tamaki, Nagambika Munaganuru, Jinho Jung, et al.
Gut (2021) Vol. 71, Iss. 5, pp. 983-990
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1137
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 3, pp. 492-542
Closed Access | Times Cited: 281
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
Rohit Loomba, Rizwana Mohseni, Kathryn Jean Lucas, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1475-1486
Open Access | Times Cited: 149
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD
Nobuharu Tamaki, Veeral Ajmera, Rohit Loomba
Nature Reviews Endocrinology (2021) Vol. 18, Iss. 1, pp. 55-66
Open Access | Times Cited: 147
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
Arun J. Sanyal, Patricia López, Eric Lawitz, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 392-400
Open Access | Times Cited: 104
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Manuel Romero‐Gómez, Eric Lawitz, R. Ravi Shankar, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 4, pp. 888-897
Open Access | Times Cited: 92
Noninvasive Assessment of Liver Fibrosis in NAFLD
Arun J. Sanyal, Laurent Castéra, Vincent Wai‐Sun Wong
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2026-2039
Closed Access | Times Cited: 70
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke, Paul Horn, Vincent Wai‐Sun Wong, et al.
Obesity Facts (2024) Vol. 17, Iss. 4, pp. 374-444
Open Access | Times Cited: 54
American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease
Jonathan G. Stine, Michelle T. Long, Kathleen E. Corey, et al.
Hepatology Communications (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 43
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
Tracey G. Simon, Robert M. Wilechansky, Stefania Stoyanova, et al.
JAMA (2024) Vol. 331, Iss. 11, pp. 920-920
Open Access | Times Cited: 39
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hannes Hagström, Ying Shang, Hannes Hegmar, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 944-956
Closed Access | Times Cited: 33
WFUMB Guidelines/Guidance on Liver Multiparametric Ultrasound. Part 2: Guidance on Liver Fat Quantification
Giovanna Ferraioli, R. Graham Barr, Annalisa Berzigotti, et al.
Ultrasound in Medicine & Biology (2024) Vol. 50, Iss. 8, pp. 1088-1098
Open Access | Times Cited: 31
Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial
Mohamed El‐Kassas, Hala Mostafa, Wessam Abdellatif, et al.
Alimentary Pharmacology & Therapeutics (2025)
Open Access | Times Cited: 4
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials
Javier Armisen, Mitra Rauschecker, Janeli Sarv, et al.
Journal of Hepatology (2025)
Closed Access | Times Cited: 2
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis
Rohit Loomba, Vlad Ratziu, Stephen A. Harrison, et al.
Gastroenterology (2021) Vol. 162, Iss. 3, pp. 680-688
Open Access | Times Cited: 86
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Vlad Ratziu, Stephen A. Harrison, V. Loustaud‐Ratti, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 3, pp. 479-492
Open Access | Times Cited: 57
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease
Nobuharu Tamaki, Masayuki Kurosaki, Daniel Q. Huang, et al.
Hepatology Research (2022) Vol. 52, Iss. 6, pp. 497-507
Open Access | Times Cited: 46
Non-Invasive Imaging Methods to Evaluate Non-Alcoholic Fatty Liver Disease with Fat Quantification: A Review
Weon Jang, Ji Soo Song
Diagnostics (2023) Vol. 13, Iss. 11, pp. 1852-1852
Open Access | Times Cited: 27
MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH
Rohit Loomba, Maral Amangurbanova, Ricki Bettencourt, et al.
Gut (2024) Vol. 73, Iss. 8, pp. 1343-1349
Closed Access | Times Cited: 12
NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics
Dimitris Kounatidis, Natalia G. Vallianou, Eleni Geladari, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 826-826
Open Access | Times Cited: 12
Incretin-based investigational therapies for the treatment of MASLD/MASH
Bram Brouwers, Girish S. Rao, Yuanyuan Tang, et al.
Diabetes Research and Clinical Practice (2024) Vol. 211, pp. 111675-111675
Open Access | Times Cited: 11
Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
Nobuharu Tamaki, Takefumi Kimura, Shun‐ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 8, pp. 1033-1041
Closed Access | Times Cited: 8
Longitudinal association of magnetic resonance elastography‐associated liver stiffness with complications and mortality
Mayu Higuchi, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 55, Iss. 3, pp. 292-301
Open Access | Times Cited: 55
Non-invasive tests of non-alcoholic fatty liver disease
Guanlin Li, Xinrong Zhang, Huapeng Lin, et al.
Chinese Medical Journal (2022) Vol. 135, Iss. 5, pp. 532-546
Open Access | Times Cited: 35
Exercise Training Is Associated With Treatment Response in Liver Fat Content by Magnetic Resonance Imaging Independent of Clinically Significant Body Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Jonathan G. Stine, Kara DiJoseph, Zach Pattison, et al.
The American Journal of Gastroenterology (2022) Vol. 118, Iss. 7, pp. 1204-1213
Closed Access | Times Cited: 32
Page 1 - Next Page

Scroll to top